For more peer-reviewed articles and publications from our data experts and customers who are utilizing Inovalon data to change healthcare, visit our research and publications hub. ow.ly/FjAg50Xt2qL

Congratulations to our research team:
Tess Donckels
Iman Mohammadi
Anthony Yu
Yecheng Huang
Tigwa Davis

These findings contribute to the growing discussion around how pricing policies and reimbursement shifts may influence availability of essential oncology drugs.

Using real-world data across 50 therapies, we found that oncology drugs with inflation adjusted declines in ASP were 6 times more likely to enter shortage.

This study examined whether declining Medicare Average Sales Price (ASP) is associated with oncology drug shortages among small-molecule injectable therapies.

FDA and other stakeholders have suggested that price erosion is a major driver of oncology drug shortages, but evidence is limited.